| |
|
Global Hepatitis Summit - AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir: An Exploratory
Post-hoc Analysis
|
| |
| |
Reported by Jules Levin
Global Hepatitis Summit 2018
The 16th International Symposium on Viral Hepatitis and Liver Disease - Toronto, Canada 16 June 2018
Tarik Asselah1, Sabela Lens2, Neddie Zadeikis3, Magdy Elkhashab4, Robert J. Fontana5, Zhenyi Xue3, Ana Gabriela Pires dos Santos3, Federico Mensa3, Robert S. Brown, Jr.6
1Hopital Beaujon & INSERM UMR 1149, Clichy, France. 2Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, Barcelona, Spain. 3AbbVie, Inc., North Chicago, Illinois, USA. 4Toronto Liver Centre, Toronto, Canada. 5Division of Internal Medicine - Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA. 6Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA.
| |
| |
| |
|
|
|
